Grohs Josef G, Schmidt Maximilian, Wanivenhaus Axel
Department of Orthopedics, Medical University of Vienna, Austria.
Acta Orthop. 2007 Feb;78(1):95-8. doi: 10.1080/17453670610013484.
Recent reports have suggested that selective COX-2 inhibition may be sufficient for the prevention of heterotopic ossification.
We performed a randomized controlled study to evaluate the effect of the selective COX-2 inhibitor rofecoxib compared to that of indomethacin on the incidence and extent of heterotopic ossification in patients who had undergone hip replacement surgery. 50 patients received a daily dose of 25 mg rofecoxib and 50 patients received a daily dose of 100 mg indomethacin (25, 25, and 50 mg).
No ossifications were found in 48 patients. Grade-II ossifications were seen in 5/46 patients in the rofecoxib group and in 6/50 patients in the indomethacin group. Grade-III and grade-IV ossifications were seen in 3/46 patients in the rofecoxib group only. The differences were not statistically significant. The study medication had to be discontinued in 2 patients in the indomethacin group, due to dyspepsia.
After short-term administration, the selective COX-2 inhibitor rofecoxib was effective in preventing heterotopic ossification after total hip arthroplasty.
最近的报告表明，选择性COX-2抑制可能足以预防异位骨化。
我们进行了一项随机对照研究，以评估选择性COX-2抑制剂罗非昔布与吲哚美辛相比，对接受髋关节置换手术患者异位骨化的发生率和程度的影响。50例患者每日服用25mg罗非昔布，50例患者每日服用100mg吲哚美辛（25mg、25mg和50mg）。
48例患者未发现骨化。罗非昔布组46例患者中有5例出现II级骨化，吲哚美辛组50例患者中有6例出现II级骨化。仅罗非昔布组46例患者中有3例出现III级和IV级骨化。差异无统计学意义。吲哚美辛组有2例患者因消化不良而不得不停用研究药物。
短期给药后，选择性COX-2抑制剂罗非昔布在预防全髋关节置换术后异位骨化方面有效。
